A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer-Reference-Cited by-同舟云学术

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer

Published:2019-06-26 Issue:1 Volume:38 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Buttarelli Marianna,Babini Gabriele,Raspaglio Giuseppina,Filippetti Flavia,Battaglia Alessandra,Ciucci Alessandra,Ferrandina Gabriella,Petrillo Marco,Marino Carmela,Mancuso Mariateresa,Saran Anna,Villani Maria Elena,Desiderio Angiola,D’Ambrosio Chiara,Scaloni Andrea,Scambia Giovanni,Gallo Daniela

Funder

Regione Campania

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-019-1268-y.pdf

Reference63 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.

3. Nicolás-Párraga S, Alemany L, de Sanjosé S, Bosch FX, Bravo IG. RIS HPV TT and HPV VVAP study groups. Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. Int J Cancer. 2017;140(9):2092–100.